Showing 21 - 40 results of 15,701 for search 'treating data', query time: 0.16s Refine Results
  1. 21

    Municipal secondary-treated effluent data seem to be a suitable source of information for human viral trends by Elsa T. Rodrigues, Joana M. Oliveira, Anália Carmo, Miguel A. Pardal, Ana M. Matos

    Published 2024-12-01
    “…From the 11 raw influent and 52 secondary-treated effluent samples tested, JC Virus data present an occurrence frequency of 100 %, showing two different abundance patterns along the year, before and after the appearance of SARS-CoV-2. …”
    Get full text
    Article
  2. 22

    Difficult-to-treat rheumatoid arthritis: predictors and prevention possibilities (analysis of the Moscow unified register of arthritis data) by E. V. Zhilyaev, G. V. Lukina, E. N. Koltsova, E. I. Schmidt, K. A. Lytkina, I. V. Pozharov

    Published 2025-01-01
    “…Conclusion. The analysis of data from the registry of patients who were in real clinical practice made it possible to identify patients who accurately meet criteria of the European Alliance of Associations for Rheumatology for difficult-to-treat RA and patients who exactly do not meet them. …”
    Get full text
    Article
  3. 23

    Real-world data suggest that geriatric assessment fails to stratify risk in treating older adults with lung cancer by Mauro Daniel Spina Donadio, Audrey Cabral F Oliveira, Luciana Leite Moura, Victor Hugo Fonseca de Jesus, Tiago Cordeiro Felisimino, Aldo Lourenço Abbade Dettino

    Published 2021-10-01
    “…The purpose of this study was to evaluate epidemiological data and clinical outcomes of patients with lung cancer treated with non-curative intent assessed by geriatric assessment (GA) and restricted access to new therapies. …”
    Get full text
    Article
  4. 24
  5. 25

    Assessing the strength of lime-treated clayey soil reinforced with PET: A ML-based data-derived approach by Javadreza Vahedi, Mehdi Koohmishi

    Published 2025-03-01
    “…To develop a ML-based data-driven approach, the standard Proctor compaction test and the point load test (PLT) are performed on prepared specimens. …”
    Get full text
    Article
  6. 26

    A mathematical model for predicting the spatiotemporal response of breast cancer cells treated with doxorubicin by Hugo J. M. Miniere, Ernesto A. B. F. Lima, Guillermo Lorenzo, David A. Hormuth II, Sophia Ty, Amy Brock, Thomas E. Yankeelov

    Published 2024-12-01
    “…MCF7 breast cancer cells were previously cultivated in wells for up to 1000 hours, treated with various concentrations of doxorubicin and imaged with time-resolved microscopy to record spatiotemporally-resolved cell count data. …”
    Get full text
    Article
  7. 27

    A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab — Actual Russian Clinical Practice Data by A. S. Kolbin, L. S. Namazova-Baranova, E. A. Vishneva, M. Y. Frolov, T. L. Galankin, A. A. Alekseeva, E. A. Dobrynina

    Published 2016-11-01
    “…It takes 39,820 rubles to prevent one hospitalization with omalizumab over a 5-year planning horizon (cost efficiency analizis), which is comparable to the cost of hospitalization (43,141 rubles). Total costs for treating 100 children with asthma, 7 of which would be treated with omalizumab, were equal to the amount of money which is enough to treat 105 children without omalizumab (analysis of budgetary influence).Conclusion: The analyses of cost efficiency and utility have shown that the strategy of using omalizumab together with standard treatment is economically expedient. …”
    Get full text
    Article
  8. 28
  9. 29

    Clinical Characteristics and Treatment Pathway of Patients Treated with Helicobacter pylori Infection-A Single Center Cohort Study Using Common Data Model by Seung In Seo, Tae Jun Kim, Yoon Jin Choi, Chang Seok Bang, Yong Kang Lee, Moon Won Lee, Su Youn Nam, Woon Geon Shin

    Published 2022-09-01
    “…We aimed to analyze the clinical characteristics of H. pylori-infected patients alongside their treatment protocols using a common data model (CDM). Materials and Methods A 16-year electronic health record (of 1,689,604 patients from 2004 to 2019) was converted into a CDM in Kangdong Sacred Heart Hospital. …”
    Get full text
    Article
  10. 30

    Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa by Angela Schulz, Angela Schulz, Christoph Schwering, Eva Wibbeler, Lena Marie Westermann, Luca Hagenah, Susanne Lezius, Ashok Jha, Abigail Hunt, Peter Slasor, Pascal Reisewitz, Miriam Nickel

    Published 2025-03-01
    “…IntroductionThis study assessed the real-world effectiveness and safety of the enzyme replacement therapy (ERT), cerliponase alfa, to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease.MethodsData from the DEM-CHILD database were analyzed, comparing patients who initiated ERT outside clinical trials with natural history (NH) controls. …”
    Get full text
    Article
  11. 31

    Primary malignant tumors of the trachea: a retrospective analysis of the clinical data of 79 patients treated in a single center by Qiuyan Chen, Keying Xue, Yigen Wu, Bingqing Luo, Yuyi Lin

    Published 2025-04-01
    “…BackgroundPrimary malignant tumors of the trachea are rare. There are few data on such tumors, the understanding of the disease is limited, and the best treatment plan has not yet been determined.MethodsClinical data obtained from the medical records of 79 patients with primary malignant tumors of the trachea treated in our hospital between August 2008 and August 2023 were retrospectively analyzed. …”
    Get full text
    Article
  12. 32

    Postmenopausal ovarian hyperandrogenism of surgically treated patients: a case report and scoping review with individual patient’s data analysis by Angelo Forte, Lanfranco D’Elia, Carmine De Luca, Antonella Fiore, Antonio Barbato, Veronica Abate, Anita Vergatti, Nunzia Verde, Gianpaolo De Filippo, Pietro Venetucci, Maria Chiara De Angelis, Rosa Maria Di Crescenzo, Francesca Grasso, Perruolo Giuseppe, Pietro Formisano, Attilio Di Spiezio Sardo, Rosario Pivonello, Domenico Rendina

    Published 2025-08-01
    “…Tumorous or non-tumorous ovarian diseases can cause PH.MethodsIn this two-section hybrid study, the first section describes the case of a patient with PH caused by an ovarian disease and surgically treated. The second section shows the results of a scoping review with individual patient data (IPD) analysis, which was performed to define the biochemical and clinical features of PH patients with tumorous or non-tumorous ovarian diseases surgically treated. …”
    Get full text
    Article
  13. 33
  14. 34
  15. 35
  16. 36

    A clinical data-driven machine learning approach for predicting the effectiveness of piperacillin-tazobactam in treating lower respiratory tract infections by Yemeng Yang, Kun Han, Jiatao Li, Tao Zhang, Zhijing Zhu, Ling Su, Zhaoyong Han, Chunyan Xu, Yi Lu, Likun Pan, Tao Yang

    Published 2025-03-01
    “…Results A total of 1,314 patients primarily treated with TZP as initial empiric antibiotic therapy were enrolled in the analysis. …”
    Get full text
    Article
  17. 37

    Longer disease progression milestone-free time in people with amyotrophic lateral sclerosis treated versus not treated with intravenous edaravone: results from an administrative cl... by James D Berry, Melissa Hagan, Jeffrey Zhang, Ying Liu, Malgorzata Ciepielewska

    Published 2025-01-01
    “…Aim: To estimate time-to-progression milestones in people with amyotrophic lateral sclerosis (PALS) treated versus not treated with intravenous (IV) edaravone (Radicava R IV, Mitsubishi Tanabe Pharma America [MTPA], hereafter ”IV edaravone”) in a real-world setting. …”
    Article
  18. 38
  19. 39

    THE CONTROL OF INTERNATIONAL NORMALISED RATIO IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH WARFARIN IN OUTPATIENT AND HOSPITAL SETTINGS: DATA FROM RECVASA REGISTRIES by M. M. Loukianov, S. Yu. Martsevich, S. S. Yakushin, A. N. Vorobyev, K. G. Pereverzeva, A. V. Zagrebelnyy, V. Val. Yakusevich, V. Vl. Yakusevich, T. A. Gomova, M. N. Valiakhmetov, V. P. Mikhin, Yu. V. Maslennikova, M. A. Bichurina, L. A. Matskevich, E. N. Belova, V. G. Klyashtorny, E. V. Kudryashov, A. D. Deev, O. M. Drapkina, s. A. Boytsov

    Published 2018-03-01
    “…To study in the RECVASA registers the availability of data about the international normalized ratio (INR) indicator and achievement of its target values in outpatient and hospital practice in patients with atrial fibrillation (AF) receiving anticoagulant therapy with warfarin.Material and methods. …”
    Get full text
    Article
  20. 40